Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation and Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05717790 is registered in ClinicalTrials.gov with Fourth Affiliated Hospital of Guangxi Medical University as lead sponsor.

NCT NCT05717790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation and Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Lead sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Phase
Not applicable
Overall status
Recruiting
Start date
December 1, 2022
Completion date
November 30, 2027
Enrollment
288 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma by ajcc v8 stage